Your ApoB Is High — A Step-by-Step Guide to What Happens Next

You got a blood test back. Maybe you specifically asked for ApoB. Maybe a doctor ordered it as part of an advanced lipid panel. Either way, the number came back above 100 mg/dL, and now you’re here — trying to figure out what that means and what you’re supposed to do about it.

This isn’t the post that tells you to eat more fiber and hope for the best. This is the step-by-step protocol: what ApoB is, why it matters more than LDL, how your specific target gets determined, and exactly what happens to bring your number down.

Step 1: Understand What ApoB Is and Why It Matters

ApoB — apolipoprotein B — is a protein. Every atherogenic lipoprotein in your blood carries exactly one molecule of it. Atherogenic lipoproteins are the particles that penetrate arterial walls and initiate plaque formation: LDL particles, VLDL remnants, IDL particles, and Lp(a) particles. One particle, one ApoB.

That makes ApoB a direct particle count. Particle count — not cholesterol content — is what drives atherosclerosis.

LDL-C, the number most people know, estimates the amount of cholesterol riding inside LDL particles. But two people with identical LDL-C can have dramatically different numbers of actual particles. One might have fewer large particles (lower risk). The other might have many small particles (higher risk). The LDL-C looks the same. The ApoB doesn’t.

An ApoB above 100 mg/dL means you have a high concentration of atherogenic particles. Each one can cross into the arterial wall and contribute to plaque. The longer your ApoB stays elevated, the more cumulative exposure your arteries absorb. Atherosclerosis is a disease of exposure over time — both the magnitude of ApoB and the duration matter.

Step 2: Find Out What Determines YOUR Target

Not everyone with a high ApoB needs the same target. Your target depends on your full risk profile — someone with additional risk factors needs a lower ApoB to achieve the same level of protection.

Here’s how risk tier assignment works:

Tier A — Very High Risk | ApoB Target: Below 55 mg/dL

You’re assigned Tier A if:

• You’ve had a prior cardiovascular event (heart attack, stroke, stent, bypass)
• Your Lp(a) — lipoprotein(a), a genetically determined particle — is above 125 nmol/L

Lp(a) is tested once because it’s genetic and doesn’t change. If your Lp(a) is above 125, your risk tier escalates regardless of other factors. Tier A means immediate pharmacotherapy — no trial period with lifestyle alone.

Tier B — High Risk | ApoB Target: Below 60 mg/dL

You’re assigned Tier B if:

• You have a family history of premature atherosclerotic cardiovascular disease (heart attack or stroke in a first-degree male relative before 55, or female relative before 65)
• Your Lp(a) is between 75 and 125 nmol/L

Family history of premature ASCVD is one of the strongest risk signals. If your father had a heart attack at 50, that changes your target.

Tier C — Moderate Risk | ApoB Target: Below 70 mg/dL

You’re assigned Tier C if:

• Your baseline ApoB is above 100 mg/dL
• You don’t meet Tier A or Tier B criteria

If you’re reading this post because your ApoB came back above 100, and you don’t have the Tier A or B risk factors above, Tier C is likely where you land. Your target is below 70 — a meaningful reduction, but achievable.

Tier D — Standard Risk | ApoB Target: Below 80 mg/dL

You’re assigned Tier D if:

• None of the above risk factors apply

Tier D members still get ApoB optimization — because an ApoB of 80 is better than an ApoB of 100, even without additional risk factors. Atherosclerosis is cumulative. Lower particle exposure over decades means less plaque.

What We Don’t Use for Risk Tier Assignment

Not every test marketed as “advanced” adds value. The Protocol Cardiovascular Risk protocol specifically excludes:

• CIMT (carotid intima-media thickness): Class III — studies show no incremental benefit for risk prediction beyond standard markers.
• LDL-P (LDL particle number): Redundant with ApoB. ApoB counts all atherogenic particles, not just LDL. One test instead of two, and ApoB captures more.
• Oxidized LDL: Unstandardized across labs. Results from one lab can’t be compared to another. Not reliable enough for clinical decisions.

Step 3: Calculate Your Gap

This is the decision point. Subtract your target from your current ApoB.

Example 1: Your ApoB is 110. Your target (Tier C) is 70. Gap = 40. Example 2: Your ApoB is 105. Your target (Tier D) is 80. Gap = 25.

The gap determines your treatment path:

Gap of 30 or Less: Lifestyle First

A gap of 30 mg/dL or less means evidence-based lifestyle modifications have a realistic chance of closing the distance. You get 12 weeks.

What those 12 weeks look like:

• Dietary changes that specifically target ApoB reduction (not generic “heart-healthy eating”)
• Exercise optimization — both aerobic and resistance training affect lipid metabolism
• Targeted supplementation where evidence supports it
• Coached accountability — because knowing what to do and doing it are different things

At 12 weeks, ApoB is rechecked. If you’ve hit your target, lifestyle modifications become your ongoing protocol with regular monitoring. If you haven’t, pharmacotherapy enters the plan.

Gap Greater Than 30: Pharmacotherapy Plus Lifestyle From Day One

A gap above 30 mg/dL means lifestyle alone is unlikely to close it. Asking someone with an ApoB of 130 and a target of 70 to close a 60-point gap through diet and exercise is setting them up for 12 weeks of continued high arterial exposure followed by the pharmacotherapy they needed from the start.

When the gap exceeds 30, both tracks start simultaneously: lifestyle modifications AND pharmacotherapy. This isn’t a failure of willpower. It’s arithmetic — the biology doesn’t support a lifestyle-only approach when the distance is that large.

Step 4: Understand What Pharmacotherapy Looks Like

If your gap puts you on the pharmacotherapy track, here’s the typical escalation:

First Line: Statins

Statins reduce ApoB by 30-50% depending on the specific statin and dose. They work by reducing the liver’s production of cholesterol, which causes the liver to pull more LDL particles out of the blood, lowering particle count.

The CTT meta-analysis — the largest analysis of statin trials ever conducted — showed that statin efficacy is equal in men and women. This matters because there’s a persistent misconception that statins don’t work as well for women. The data says otherwise.

Side effects are real but less common than many people believe. Muscle symptoms occur in roughly 5-10% of patients, and most resolve with a switch to a different statin or dosing schedule.

Second Line: Ezetimibe

If a statin alone doesn’t reach your target, ezetimibe is typically added. Ezetimibe blocks cholesterol absorption in the intestine, producing an additional 15-20% reduction in ApoB when combined with a statin. It’s well-tolerated, once-daily, and has been used for decades.

Third Line: PCSK9 Inhibitors

For members who need further reduction — or who can’t tolerate statins — PCSK9 inhibitors are injectable medications given every 2-4 weeks that can reduce ApoB by an additional 50-60%. These are highly effective and typically reserved for Tier A and Tier B members or anyone who can’t reach their target with statins and ezetimibe.

The escalation is methodical. Start with the most established, best-tolerated option. Add layers only as needed. Recheck ApoB at each step to confirm the intervention is working.

Step 5: Know What Lifestyle Changes Actually Move ApoB

Not all lifestyle advice is equal. These are the modifications with evidence for ApoB reduction specifically:

Dietary changes with the largest effect:

• Reducing saturated fat intake has the most consistent impact on ApoB. Replacing saturated fat with unsaturated fat (not with refined carbohydrates) is the specific move.
• Soluble fiber — oats, legumes, psyllium — binds bile acids and forces the liver to pull more LDL particles from circulation. 10-25 grams per day of soluble fiber can lower ApoB by 5-10%.
• Plant sterols and stanols block cholesterol absorption — similar mechanism to ezetimibe, but smaller effect. 2 grams per day can contribute an additional 5-10% reduction.

Exercise:

• Regular aerobic exercise (150+ minutes per week of moderate intensity) improves lipid metabolism broadly. The effect on ApoB specifically is modest — typically 5-10% — but it compounds with dietary changes and contributes to overall metabolic health.

What doesn’t move ApoB much:

• Generic advice to “eat healthy” without specific targets
• Supplements marketed for cholesterol that lack evidence for ApoB reduction
• Extreme dietary protocols that aren’t sustainable beyond a few weeks

Step 6: Understand the Timeline

ApoB responds to intervention in 6-12 weeks. That’s true for both lifestyle changes and pharmacotherapy. This is one of the advantages of using ApoB as the primary marker — it gives you relatively fast feedback on whether your protocol is working.

The 12-week recheck is the accountability moment. Either your ApoB is moving toward your target, or it isn’t. If it is, you stay the course. If it isn’t, the plan adjusts — typically by adding the next layer of pharmacotherapy or refining lifestyle modifications that aren’t producing the expected effect.

This is not a “check again in a year” approach. Twelve weeks. Measure. Adjust. Repeat until target is reached.

What This Looks Like at Protocol

The Cardiovascular Risk protocol is built around this exact sequence. Every member gets:

1. ApoB measurement at baseline — along with Lp(a) (tested once), standard lipid panel, and additional markers as indicated
2. Risk tier assignment based on the full clinical picture
3. Gap calculation and treatment path determination
4. A specific, coached protocol — not a pamphlet, not a printout, not “eat better and come back in six months”
5. 12-week recheck with protocol adjustment based on results

Protocol members who complete the Cardiovascular Risk protocol see ApoB optimal attainment improve from 27% at baseline to 69% — a shift driven by specific targets, coached interventions, and systematic follow-through.

The Difference Between Knowing and Doing

You now know more about ApoB than most people who get a high result. You know what determines your target, how the gap rule works, what pharmacotherapy escalation looks like, and what lifestyle changes have actual evidence behind them.

Where most people stall is the gap between knowing this and acting on it. They read the post, feel informed, and go back to waiting for their next annual physical. The number stays where it is. The arterial exposure continues.

Acting on it means getting your risk tier assigned by someone who uses this framework. A specific target. A specific protocol. A 12-week accountability checkpoint. Measuring, not guessing.

Ready to get a specific plan for your ApoB? Book a Discovery Call and we’ll assign your risk tier, calculate your gap, and build the protocol to close it.